多发性硬化症复发风险因素跨治疗时代
Evan Madill, Brian Healy1, Mariann Polgar-Turcsanyi2
1Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA Department of Neurology, Harvard Medical School, Boston, MA, USA.
Multiple sclerosis journal - experimental, translational and clinical
|December 25, 2025
概括
多发性硬化症 (MS) 复发风险因素在早期和最近的治疗时期之间没有显著变化. 年龄较小和疗法效率较低仍然是关键预测因素,尽管个体风险各不相同.
科学领域:
- 神经学 神经学
- 临床研究 临床研究
- 流行病学 流行病学
背景情况:
- 多发性硬化症 (MS) 复发活动受年龄和性别的影响.
- 不断变化的治疗模式对MS复发风险因素的影响尚不清楚.
研究的目的:
- 评估多发性硬化症 (MS) 患者临床复发的预测因素.
- 为了比较不同治疗时期的复发风险因素.
主要方法:
- 对2192名患有临床隔离综合征或复发性MS的成年人的回顾性队列研究.
- 患者被分为"早期" (1997-2010) 和"最近" (2010-2020) 的治疗时期.
- 多变量逻辑回归分析了第一次访问 (FV) 后3年内复发预测因素.
主要成果:
- 年龄较小,女性性别,复发性复发性疾病,以前的复发和平台治疗预测了早期队列中的复发.
- 年龄,MS家族病史和平台治疗预测了最近队列中的复发.
- 模型的准确性在各个时代都是一致的;交互条款并不重要.
结论:
- 多发性硬化症 (MS) 复发预测因素在治疗时期之间没有显著差异.
- 年龄较小和疗法效率较低被确定为首次诊所 (FV) 的显著风险因素.
- 个人复发风险显示出显著的异质性.
相关概念视频
Psychological and Sociocultural Causes of Schizophrenia
438
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
438
Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
224
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
224


